{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:15:50Z","timestamp":1791490550226,"version":"4.3.4"},"reference-count":35,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Rezafungin is a long-acting, intravenously administered echinocandin for the treatment of candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and\/or IC was demonstrated in the Phase 3 ReSTORE study based on the primary endpoints of day 14 global cure and 30-day all-cause mortality. Here, an analysis of ReSTORE data evaluating efficacy outcomes by baseline\n              <jats:italic>Candida<\/jats:italic>\n              species is described. Susceptibility testing was performed for\n              <jats:italic>Candida<\/jats:italic>\n              species using the Clinical and Laboratory Standards Institute reference broth microdilution method. There were 93 patients in the modified intent-to-treat population who received rezafungin; 94 received caspofungin. Baseline\n              <jats:italic>Candida<\/jats:italic>\n              species distribution was similar in the two treatment groups;\n              <jats:italic>C. albicans<\/jats:italic>\n              (occurring in 41.9% and 42.6% of patients in the rezafungin and caspofungin groups, respectively),\n              <jats:italic>C. glabrata<\/jats:italic>\n              (25.8% and 26.6%), and\n              <jats:italic>C. tropicalis<\/jats:italic>\n              (21.5% and 18.1%) were the most common pathogens. Rates of global cure and mycological eradication at day 14 and day 30 all-cause mortality by\n              <jats:italic>Candida<\/jats:italic>\n              species were comparable in the rezafungin and caspofungin treatment groups and did not appear to be impacted by minimal inhibitory concentration (MIC) values for either rezafungin or caspofungin. Two patients had baseline isolates with non-susceptible MIC values (both in the rezafungin group: one non-susceptible to rezafungin and one to caspofungin, classified as intermediate); both were candidemia-only patients in whom rezafungin treatment was successful based on the day 30 all-cause mortality endpoint. This analysis of ReSTORE demonstrated the efficacy of rezafungin for candidemia and IC in patients infected with a variety of\n              <jats:italic>Candida<\/jats:italic>\n              species.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.01584-23","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T12:45:39Z","timestamp":1711370739000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":28,"title":["Outcomes by\n            <i>Candida<\/i>\n            spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and\/or invasive candidiasis"],"prefix":"10.1128","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-0828","authenticated-orcid":true,"given":"Jeffrey B.","family":"Locke","sequence":"first","affiliation":[{"name":"Cidara Therapeutics, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris M.","family":"Pillar","sequence":"additional","affiliation":[{"name":"Science and Operations, Microbiologics, Kalamazoo, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":true,"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia G.","family":"Carvalhaes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-9950","authenticated-orcid":true,"given":"David","family":"Andes","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5184-1182","authenticated-orcid":false,"given":"Jalal A.","family":"Aram","sequence":"additional","affiliation":[{"name":"Medical Affairs, Melinta Therapeutics, LLC, Parsippany, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Andrzejewski","sequence":"additional","affiliation":[{"name":"Medical Affairs, Melinta Therapeutics, LLC, Parsippany, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Bartizal","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita F.","family":"Das","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Sandison","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine and Department of Medical Microbiology and Immunology, University of California Davis Medical Center, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Pappas","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11060718"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad139"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa193"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12039"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.759408"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.26"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/ffunb.2022.1010782"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy358"},{"key":"e_1_3_3_11_2","unstructured":"US Food and Drug Administration. 2023. Rezzayo prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217417s000lbl.pdf. Retrieved 12 Jun 2023."},{"key":"e_1_3_3_12_2","unstructured":"European Medicines Agency. 2024. Rezzayo (rezafungin) summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rezzayo-epar-product-information_en.pdf. Retrieved 1 Feb 2024."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02324-8"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2020-0217"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02154-17"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw214"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.02449-21"},{"key":"e_1_3_3_18_2","volume-title":"Performance standards for antifungal susceptibility testing of yeasts [M27M44S]","author":"Clinical and Laboratory Standards Institute","year":"2022","unstructured":"Clinical and Laboratory Standards Institute. 2022. Performance standards for antifungal susceptibility testing of yeasts [M27M44S]. 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"},{"key":"e_1_3_3_19_2","unstructured":"US Food and Drug Administration. 2023. Rezafungin injection. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/rezafungin-injection. Retrieved 13 Jul 2023."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00136-13"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3616-3623.2005"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3171-3177.2005"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.01.014"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.1.40"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00708-23"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00872-6"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01430-10"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx448"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02614-17"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab431"},{"key":"e_1_3_3_31_2","unstructured":"US Food and Drug Administration. 2023. Rezafungin injection for treatment of candidemia and invasive candidiasis. Sponsor Briefing Document. Antimicrobial Drugs Advisory Committee. Available from: https:\/\/www.fda.gov\/media\/164668\/download. Retrieved 13 Jul 2023."},{"key":"e_1_3_3_32_2","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts [M27]","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. Reference method for broth dilution antifungal susceptibility testing of yeasts [M27]. 4th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"4"},{"key":"e_1_3_3_33_2","unstructured":"Joshi NA Fass JN. 2011. Sickle: a sliding-window adaptive quality-based trimming tool for FastQ files (version 1.33). Software. Available from: https:\/\/github.com\/najoshi\/sickle. Retrieved 21 Aug 2023."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-S1-S7"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1089\/cmb.2013.0084"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00906-17"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01584-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01584-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T13:03:41Z","timestamp":1714655021000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01584-23"}},"subtitle":[],"editor":[{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,2]]}},"alternative-id":["10.1128\/aac.01584-23"],"URL":"https:\/\/doi.org\/10.1128\/aac.01584-23","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"2023-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01584-23"}}